Regeneron Pharmaceuticals traded at $628.71 this Friday August 12th, increasing $4.81 or 0.77 percent since the previous trading session. Looking back, over the last four weeks, Regeneron Pharmaceuticals gained 4.43 percent. Over the last 12 months, its price rose by 0.63 percent. Looking ahead, we forecast Regeneron Pharmaceuticals to be priced at 596.61 by the end of this quarter and at 548.40 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
628.71
Daily Change
0.77%
Yearly
0.63%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Kyowa Hakko Kirin 3,185.00 65.00 2.08% -7.95%
Astellas Pharma 2,034.50 20.00 0.99% 13.75%
AbbVie 142.60 0.52 0.37% 22.42%
Agenus 2.97 0.30 11.24% -51.71%
Agios Pharmaceuticals 28.15 2.16 8.31% -35.95%
Alimera Sciences 6.73 -0.04 -0.59% -7.93%
Alnylam Pharmaceuticals 233.85 4.46 1.94% 18.98%
Amgen 248.39 0.04 0.02% 8.15%
AstraZeneca 10,712.00 206.00 1.96% 27.13%
Biogen 220.99 2.77 1.27% -35.43%
Bluebird Bio 6.72 0.41 6.50% -63.62%
BioMarin Pharmaceutical 95.07 0 0% 26.71%
Bristol-Myers Squibb 75.57 1.11 1.49% 11.94%
Esperion Therapeutics 6.70 0.06 0.90% -51.83%
Gilead Sciences 62.96 0.51 0.82% -11.52%
GlaxoSmithKline 1,450.00 50.00 3.57% -2.80%
Intercept Pharmaceuticals 17.60 1.53 9.52% 17.96%
Incyte Corp 73.99 0.23 0.31% 0.71%
Ionis Pharmaceuticals 44.10 0.66 1.52% 11.14%
J&J 165.30 -1.84 -1.10% -6.21%
Eli Lilly 308.08 6.91 2.29% 16.60%
Merck & Co 91.02 2.09 2.35% 18.64%
Moderna Inc 171.18 -0.63 -0.37% -56.08%
Neurocrine Biosciences 105.63 0.75 0.72% 18.53%
Novartis 80.10 -0.94 -1.16% -6.82%
Novartis 85.68 0.10 0.12% -8.69%
Iveric bio Inc. 13.48 0.45 3.45% 42.19%
Opthea Ltd 1.39 0.01 0.72% 11.20%
Puma Biotechnology 3.51 -0.04 -1.13% -51.65%
Pfizer 50.11 1.82 3.77% 3.36%
Ultragenyx Pharmaceutical 51.57 0.32 0.62% -44.39%
Regeneron Pharmaceuticals 628.71 4.81 0.77% 0.63%
Roche Holding 315.00 4.85 1.56% -14.39%
Seattle Genetics 170.14 -3.90 -2.24% 8.76%
Sanofi 44.37 0.95 2.19% -14.28%
Sarepta Therapeutics 109.00 -0.26 -0.24% 36.35%
Teva Pharmaceutical Industries Ltd 3,644.00 8.00 0.22% 12.43%
United Therapeutics 217.10 -3.31 -1.50% 7.15%
Vertex Pharmaceuticals 294.52 2.36 0.81% 51.53%

Indexes Price Day Year
US500 4280 72.88 1.73% -4.20%
USND 13047 267.27 2.09% -11.98%
USNDX 13566 273.89 2.06% -10.38%

Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc. is a biotechnology company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious diseases. The Company commercializes medicines and product candidates for eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, infectious diseases, and rare diseases. The Company's marketed products include EYLEA (aflibercept) Injection, Dupixent (dupilumab) Injection, Libtayo (cemiplimab) Injection, Praluent (alirocumab) Injection, Kevzara (sarilumab) Solution for Subcutaneous Injection, Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn) Injection, ARCALYST (rilonacept) Injection for Subcutaneous Use and ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion.